Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency

Metastatic dissemination in breast cancer patients occurs early in malignant transformation, raising questions about how disseminated cancer cells (DCC) progress at distant sites. Here, the authors show that DCCs in bone marrow are activated via IL6-trans-signaling and thereby acquire stemness trait...

Full description

Saved in:

Bibliographic Details
Main Authors:	Melanie Werner-Klein, Ana Grujovic, Christoph Irlbeck, Milan Obradović, Martin Hoffmann, Huiqin Koerkel-Qu, Xin Lu, Steffi Treitschke, Cäcilia Köstler, Catherine Botteron, Kathrin Weidele, Christian Werno, Bernhard Polzer, Stefan Kirsch, Miodrag Gužvić, Jens Warfsmann, Kamran Honarnejad, Zbigniew Czyz, Giancarlo Feliciello, Isabell Blochberger, Sandra Grunewald, Elisabeth Schneider, Gundula Haunschild, Nina Patwary, Severin Guetter, Sandra Huber, Brigitte Rack, Nadia Harbeck, Stefan Buchholz, Petra Rümmele, Norbert Heine, Stefan Rose-John, Christoph A. Klein
Format:	article
Language:	EN
Published:	Nature Portfolio 2020
Subjects:	Science Q
Online Access:	https://doaj.org/article/852fb79d2cfa456b923be4f3ce115b15
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency

Similar Items